Patient assistance programs (PAPs) emerged to help patients who lack health insurance or prescription drug coverage obtain ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

specialty pharmacies are responsible for distributing therapies to the patient on behalf of the manufacturer, so they need a centralised application to support the entire process of patient intake ...

The clerical overhead of enrolment forms navigated ... efficient copay assistance programs to understand the patient journey in depth. Cost: technology should reduce program overhead.

Tumour necrosis factor inhibitors (TNFi) are biopharmaceuticals used in refractory forms of the disease ... two patients because of a protocol deviation and one patient because of drug-induced liver ...

On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

AbbVie's success with Humira is a textbook example. Humira (adalimumab) is an immunosuppressant drug used to treat several autoimmune diseases, in which a patient's immune system attacks healthy ...

"Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q.

“We recognize that those with rare diseases often have complex needs that go unmet by traditional assistance,” said Green.

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...